We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Neuropharm | NPH | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 11.50 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 11.50 | 11.50 |
| Top Posts |
|---|
Posted at 24/3/2011 19:28 by lombiff muzoman - still no payment from Barclays - they have told me they spoke with the administrators and that a payment would be coming, but that was about four weeks ago. Will be chasing again in the morning.Hey Mike - glad you're recovered your losses - I'll end up losing about £40K here, but have had a spectacular time over the last six months, and have made the loss back many times over. I still have a few small pharma/biotechs, and have had mixed results - I'm well down on ASM and SLN but I was in SAR at 0.3p and sold 10% of them at 3p so the rest are on a free ride. Otherwise, I remain heavily exposed to junior gold and see that bull running for another 12-18 months. All the best, and best wishes to all former NPH holders |
Posted at 11/2/2011 13:01 by lombiff Good afternoon all - this is a nice surprise as I thought we'd only get another ha'penny or so when they settle with HMRC. It sounds like we may still get that, so the 2.4p is a bonus. Surprising there is nothing on the Neuropharm website, but at least encouraging that pelleeds and balcony have received theirs.muzo, I'm also with Barclays and no payment has arrived yet - I've asked my relationship manager to look into it. Good luck to all and hope you've managed to recover any NPH losses elsewhere - my total loss here will end up being around £40K but have had a good run with others lately. All the best |
Posted at 08/2/2011 10:17 by alchemy30 Hi all,Bingham thanks for the info, can anyone confirm whether they have received the payment. I had some with Lloydssharedealing and the last payment was automatically credited to my account, however this time there is nothing, I have raised a query with them as NPH no longer shows in my portfolio either and will let you know what reply I receive. Thanks |
Posted at 29/9/2010 13:14 by lombiff Thanks muzoman - like you, I am not a short-termer, I built my position in NPH gradually over 12 months, and was prepared to stay for 2-3 years to get full value. I also liked the story here, and what the company was trying to achieve. I'm just glad they made an early decision to return funds - some others would have milked it until all the cash was gone.I have no problem making losses like this - it's part of the game. I've made all of that and much more back in the last two months (have been heavily into several junior gold explorers since summer 2009 so am now well in the money on those). Good luck with yours |
Posted at 29/9/2010 08:46 by muzoman Sorry to hear that Lombiff. My loss was not as great as yours. Not a day or short term trader. Rather a medium to long term. I suppose one has to keep so close to companies like NPH but trying to keep track is sometimes almost impossible. As the saying goes 'We live and die by the decisions we make.Best of luck with your future investment decisions. Mman |
Posted at 02/6/2010 18:29 by pelleeds1980 Just reading the FAQs on the NPH site:How long will the liquidation process take? The final payment is normally made after tax clearance from HM Revenue & Customs has been received and all other matters (including the elimination of the subsidiary companies) have been finalised. This is estimated to take up to 18 months. --- Didnt realise Id have that long to wait for the cash |
Posted at 18/5/2010 12:45 by boobly 15p `ish in July then ?Better than 11p now . (Let`s hope there are no `Labour Like Skeletons` in the NPH Lockers .) |
Posted at 20/4/2010 12:09 by lombiff G2AM - it's always tough to take these, but you have to move on and make up the losses on others. I've been bitten fairly hard over the years but still enjoy the adrenaline when you've picked a winner.I went into NPH with my eyes open, but perhaps relied too heavily on the Edison research note saying 40p, even without NPL-2008. Will dust myself down, and move on - have made much more on SHG than I've lost on NPH, and I stayed fully invested throughout the downturn so I've bounced back nicely. All the best with yours |
Posted at 20/4/2010 06:19 by hadronuk Voluntary LiquidationTIDMNPH RNS Number : 4483K Neuropharm Group PLC 20 April 2010 ? +------------------- | For immediate release | 20 April 2010 | +------------------- Neuropharm Group plc ("Neuropharm" or "the Company") Proposed Members' Voluntary Liquidation and proposed cancellation of admission of Ordinary Shares to trading on AIM Neuropharm Group plc (AIM: NPH) today announces that its directors have decided to recommend to shareholders that the Company be wound up by way of a members' voluntary liquidation ("MVL") such that, following payment of the Company's liabilities, its remaining cash be returned to shareholders. The MVL is conditional upon approval by Neuropharm shareholders ("Shareholders") at a general meeting (the "General Meeting"), to be held on Tuesday 18 May 2010. The Company also announces that it has applied for the cancellation of the trading of its securities on AIM, subject to approval by Shareholders of the MVL. A single resolution (the "Resolution") will be proposed to Shareholders at the General Meeting to approve the MVL and the cancellation. It is expected that suspension of the Company's ordinary shares (the "Ordinary Shares") will occur at 7.00 a.m. on Tuesday 18 May 2010 and, subject to the passing of the Resolution, that cancellation will occur at 7.00 a.m. on the following day, Wednesday 19 May 2010. A circular providing further details of the proposed MVL and cancellation and the General Meeting has been posted to Shareholders today. The circular is also available on the Company's website at www.neuropharm.co.uk The Directors consider the Resolution to be in the best interests of the Company and its Shareholders. Accordingly, the Directors unanimously recommend that Shareholders vote in favour of the Resolution as they have undertaken to do in respect of the Ordinary Shares in which they are beneficially interested. The Company has received undertakings to vote in favour of the Resolution from certain Shareholders (including from those of the Directors who hold Ordinary Shares) in respect of an aggregate of 10,612,915 Ordinary Shares, representing approximately 33.65 per cent. of the current issued share capital of the Company. The Company has also received non-binding letters of intent from certain Shareholders confirming their intention to vote in favour of the Resolution in respect of an aggregate of 5,573,538 Ordinary Shares, representing approximately 17.67 per cent. of the Company's issued share capital as at the date of the Circular. Accordingly, in aggregate, the Company has received undertakings or letters of intent to vote in favour of the Resolution in respect of 16,186,453 Ordinary Shares, representing approximately 51.32 per cent. of the Company's issued share capital as at the date of the Circular. Background to and reasons for the MVL and Cancellation The Company announced on 18 February 2009 that its Phase III SOFIA study of its lead programme, NPL-2008, in autistic disorder did not achieve its primary endpoint. The SOFIA study showed that repetitive behaviours in patients were reduced after both NPL-2008 (a novel formulation of fluoxetine) and placebo treatment, but the study did not meet its primary endpoint of demonstrating a statistically significant difference between the two groups of patients. These results were unexpected and hugely disappointing to, among others, the Company and its management and shareholders. Subsequent to these results, Neuropharm sought to secure a collaboration with a pharmaceutical company to continue development of NPL-2008 and undertook discussions with a number of third party pharmaceutical companies with a view to securing a potential collaboration that would encompass the further development and commercialisation of NPL-2008. However, discussions with potential collaborators did not come to fruition. On 3 November 2009, the Company announced that it was in discussions which may or may not lead to an offer being made for the Company and noted that the Board was seeking a sale or merger of the Company in order that the value of its pipeline could be maximised. On 10 March 2010 the Company announced that it was continuing talks with a potentially interested party but that in light of the uncertainty as to whether an offer would be made for the Company and the costs associated with maintaining admission of the Company's shares to trading on AIM and the continued operation of the business, the Board had resolved to explore a return of cash to Shareholders. On 31 March 2010 the Company announced that, while discussions were ongoing for the sale of certain assets, the Company had received confirmation that none of the companies it was in discussion with were considering making an offer for the Company. The Board has therefore expended considerable time and energy in recent months considering in detail the Company's strategic options. Discussions have been held with various third parties, including already listed trade players, other international pharmaceutical companies and venture capitalists. The range of possible transactions which the Company has considered has been extensive and has included technology licensing arrangements, the sale of one or more of the Group's programmes, the sale of Neuropharm Limited, an acquisition of the Company for cash and a reverse takeover of the Company. Regrettably the Directors have now concluded that it is in the best interests of Shareholders that a resolution be proposed to, amongst other things, place the Company into members' voluntary liquidation such that, after payment of the Company's liabilities, the Company's remaining cash be returned to Shareholders via the MVL. The MVL and Cancellation It is proposed that Samantha Jane Keen and Ian Carr of Grant Thornton UK LLP, No 1 Dorset Street, Southampton SO15 2DP be appointed as joint liquidators of the Company (the "Proposed Liquidators"). It will be the Proposed Liquidators' responsibility to deal with the conduct of the MVL and to determine the timing and amount of any distribution(s) to Shareholders. The MVL is conditional upon the passing of the Resolution at the General Meeting. If the Resolution is passed, it is anticipated that the MVL will commence immediately following the General Meeting and that the appointment of the Proposed Liquidators to the Company will become effective at such time. On 19 April 2010, and as required by Section 89 of the Insolvency Act 1986 in respect of a members' solvent voluntary liquidation, the Directors made a statutory declaration of solvency stating that they have made a full enquiry into the affairs of the Company and that, having done so, they have formed the opinion that the Company will be able to pay its debts in full, together with any interest, within a period of 12 months from the commencement of the Liquidation. Whilst the timetable for any distribution is outside the Board's control, the Board currently anticipates that the Proposed Liquidators will be in a position to pay a distribution to Shareholders approximately two months following the commencement of the Liquidation. As noted above, as at 31 December 2009 the Company had net cash, cash equivalents and money market investments of GBP6.18 million. Pursuant to Rule 41 of the AIM Rules, the Company has today made an application to the London Stock Exchange for the admission of the Ordinary Shares to trading on AIM to be cancelled on 19 May 2010 subject to Shareholder approval by the passing of the Resolution at the General Meeting. It is expected that dealings in Ordinary Shares on AIM will be suspended at the start of business on 18 May 2010 (being the day of the General Meeting) and, provided the Resolution is passed, that admission of the Company's shares to trading on AIM will be cancelled with effect from the start of business on 19 May 2010. The Board On 9 April 2010 the Company announced that Dr Mike Snape had stepped down as an employee and director of the Company. Dr Acton, Stephen Whybrow and Graeme Hart, the Company's non-executive directors, have each agreed that they would waive their contractual entitlement to three months' notice in the event of the termination of their appointment as directors of the Company. Accordingly, if the Resolution is passed, each of the non-executive directors will cease to be directors from that date and will not receive any compensation for loss of office. Unless the Company enters into alternative arrangements with Robert Mansfield and Graham Yeatman, Robert Mansfield and Graham Yeatman will continue to receive their contractual entitlements under their service agreements until expiry on 22 March 2011 of their 12 month notice period. Effecting Transactions in Ordinary Shares following the MVL and Cancellation If the Resolution is approved the Ordinary Shares will no longer be tradable on AIM. Furthermore, as a consequence of the MVL, the Ordinary Shares will not be transferrable without the consent of the appointed Proposed Liquidators. Further details regarding dealings, transfers and cancellation of admission are provided in the circular to Shareholders. Enquiries For further information please contact: +------------------- | Neuropharm | + 44 (0) 1372 | | | 371 171 | +------------------- | Robert Mansfield, Chief Executive | | | Officer | | | Graham Yeatman, Chief Financial | | | Officer | | +------------------- | | | +------------------- | Piper Jaffray Ltd. | + 44 (0) 20 | | | 3142 8700 | +------------------- | Neil Mackison, Rupert Winckler | | +------------------- | | | +------------------- | Buchanan Communications | + 44 (0) 20 | | | 7466 5000 | +------------------- | Mark Court, Catherine Breen | | +------------------- Notes to Editors: About Neuropharm Neuropharm is a speciality pharmaceutical company focused on the development of medicines for the treatment and management of neurodevelopmental disorders. Please visit www.neuropharm.co.uk for further information. This information is provided by RNS The company news service from the London Stock Exchange END MSCUROSRRWASURR |
Posted at 01/2/2010 09:31 by boobly NPH is very intelligent and load cash reserver - No debt, This is reason they can steer north and excellent contracts world wide. Takeover at 20p even so cheap - NPH is ascertain for merger for the best interest.? NPH has very valuable IP and loads of cash in reserve - No debt. This is the reason why they will move north . They have excellent contracts world wide . A takeover , even at 20p would be cheap - NPH will seek a merger to serve their best interests . ? I think I concur with that , but the wait is very frustrating ;>) (NOI) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
